Related Experiment Video
Updated: Jan 23, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With
Wen Xiong1, Yusha Wang2, Tingyan He3
1Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China.
OGFRL1 deficiency is a newly identified cause of Chronic Recurrent Multifocal Osteomyelitis (CRMO). This study reveals OGFRL1
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Chronic Recurrent Multifocal Osteomyelitis (CRMO) is a rare autoinflammatory bone disorder.
- The genetic basis of CRMO is not fully understood, with limited identified causative variants.
Purpose of the Study:
- To investigate the role of a specific OGFRL1 loss-of-function variant in CRMO pathogenesis.
- To elucidate the underlying molecular mechanisms contributing to CRMO in patients with OGFRL1 deficiency.
Main Methods:
- Whole exome and Sanger sequencing to identify and confirm the OGFRL1 variant.
- Analysis of inflammatory signatures using qPCR, ELISA, CBA, and RNA sequencing (bulk and single-cell).
- Collagen antibody-induced arthritis (CAIA) model in Ogfrl1 knockout mice and in vitro osteoclast differentiation assays.
Main Results:
- The patient exhibited activated inflammatory pathways (MAPK, NF-κB) and cytokine overproduction.
- Ogfrl1 knockout mice showed exacerbated arthritis, bone erosion, and enhanced osteoclast differentiation.
- The patient demonstrated a positive response to TNF inhibitor therapy, with reduced inflammatory markers and improved bone lesions.
Conclusions:
- OGFRL1 deficiency is identified as a novel genetic cause of CRMO.
- OGFRL1 plays a crucial role in suppressing inflammatory responses.
- This study offers new insights into CRMO pathogenesis and potential therapeutic strategies.
More Related Videos
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Therapeutic Index
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Microorganisms in Medicine and Therapeutics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...